Please assess the completion status of the following clinical trial:

Trial Title: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria~* Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome)~* Age 18 years or older~* Relapsed or refractory to at least 1 prior systemic therapy~* Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Life expectancy ≥ 6 months~* Adequate respiratory function~* Adequate bone marrow function~* Adequate renal and hepatic function~Key Exclusion Criteria~* Known central nervous system (CNS) involvement by lymphoma~* Previously received immune checkpoint therapy~* Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer~* Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions~* Severe or debilitating pulmonary disease~* Clinically significant cardiovascular disease~* Active fungal, bacterial, and/or viral infection requiring systemic therapy~* Known infection with HIV or active viral hepatitis B or C infection~* Major surgery within 4 weeks of the first dose of study drug~* Pregnant or lactating women~* Vaccination with a live vaccine within 35 days prior to the first dose of study drug~* Hypersensitivity to tislelizumab~* Concurrent participation in another therapeutic clinical trial~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: ENKTL (Type: EXPERIMENTAL): Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- Cohort 2: PTCL-NOS, AITL, and ALCL (Type: EXPERIMENTAL): Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- Cohort 3: MF and SS (Type: EXPERIMENTAL): Participants with R/R cutaneous T-cell lymphoma \[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete